AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Huntington's Disease Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a rare neurodegenerative condition. This designation ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

A drug originally developed for high blood pressure could find a new use in the treatment of Huntington's disease, thanks to an artificial intelligence-based drug discovery programme at Spain's ...

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...

HUNTINGTON, W.Va. (WCHS) — A summer concert series is making a return to Huntington in 2025. The city’s 9th Street Live calendar will include regional musical talent performing on Friday evenings.

Huntington Bank CEO Steve Steinour expressed optimism about the economy despite recent tariff volatility. Huntington reported increased earnings per share and net income in the first quarter of 2025.

The latest brand to throw its hat in the ring was Marks & Spencer, and it did so by tapping none other than Rosie Huntington-Whiteley. One of the woes (or joys, depending on how you see it ...